Revelation Biosciences Valuation
| REVB Stock | USD 4.18 0.13 3.02% |
At this time, the company appears to be undervalued. Revelation Biosciences holds a recent Real Value of $6.0 per share. The prevailing price of the company is $4.18. Our model determines the value of Revelation Biosciences from analyzing the company fundamentals such as Return On Equity of -2.7, shares owned by institutions of 11.80 %, and Shares Outstanding of 522.28 K as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Revelation Biosciences' price fluctuation is very risky at this time. Calculation of the real value of Revelation Biosciences is based on 3 months time horizon. Increasing Revelation Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Revelation Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Revelation Stock. However, Revelation Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.18 | Real 6.0 | Hype 3.75 |
The real value of Revelation Stock, also known as its intrinsic value, is the underlying worth of Revelation Biosciences Company, which is reflected in its stock price. It is based on Revelation Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Revelation Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Revelation Biosciences helps investors to forecast how Revelation stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Revelation Biosciences more accurately as focusing exclusively on Revelation Biosciences' fundamentals will not take into account other important factors: Revelation Biosciences Total Value Analysis
Revelation Biosciences is at this time anticipated to have valuation of (4.29 M) with market capitalization of 2.18 M, debt of 5.56 M, and cash on hands of 3.48 M. The negative valuation of Revelation Biosciences may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Revelation Biosciences fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(4.29 M) | 2.18 M | 5.56 M | 3.48 M |
Revelation Biosciences Asset Utilization
One of the ways to look at asset utilization of Revelation is to check how much profit was generated for every dollar of assets it reports. Revelation Biosciences holds a negative application of assets of -0.51 pct., losing $0.005098 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Revelation Biosciences shows how discouraging it operates for each dollar spent on its assets.Revelation Biosciences Ownership Allocation
Roughly 88.1 pct. of Revelation Biosciences outstanding shares are held by general public with 0.1 % owned by insiders and only 11.8 (%) by third-party entities. On August 6, 2019, Senator Pat Toomey of US Senate acquired $15k to $50k worth of Revelation Biosciences's common stock.Revelation Biosciences Profitability Analysis
Net Loss for the year was (120.25 K) with profit before overhead, payroll, taxes, and interest of 90.91 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Revelation Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Revelation Biosciences and how it compares across the competition.
About Revelation Biosciences Valuation
The stock valuation mechanism determines Revelation Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Revelation Biosciences. We calculate exposure to Revelation Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Revelation Biosciences's related companies.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company was founded in 2020 and is based in San Diego, California. Revelation Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Revelation Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 228.6 K | |
| Forward Price Earnings | 0.8875 |
Complementary Tools for Revelation Stock analysis
When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |